Pharma Services

The XCell® ATF system leverages alternating tangential flow (ATF) technology to dramatically simplify upstream intensification and boost cell densities up to 10x, all while reducing facility footprint and cost of goods. Using a diaphragm pump, the system retains cells within the bioreactor, enabling high-density perfusion or seed-train intensification.

With a scalable portfolio of single-use and stainless-steel devices—ranging from 0.5 L up to 5,000 L bioreactor volumes—and intuitive controllers, the XCell ATF system enables seamless scale-up from process development to commercial manufacturing. Its integrated hardware and software design streamlines operations and delivers consistent process performance. The XCell Lab controller supports up to eight devices via a manifold, while the larger LS controller supports dual ATF devices, both offering flow sensors, permeate pressure monitoring, and 21 CFR Part 11 compliance.

This technology is ideal for bioprocessing applications such as N-1 perfusion, long-term perfusion, media exchange, and seed-train intensification. By increasing volumetric productivity, it helps reduce manufacturing time and bioreactor volume, thereby optimizing facility utilization and minimizing capital expenditure.